SCHEMBL17136160

SCHEMBL17136160

CCCc1cc(C)[nH]c(=O)c1CNC(=O)c1cc(-c2ccc(CN3CCCN(C)CC3)nc2)cc(N(CC)C2CCOCC2)c1C

nearest known ligand 0.87

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 20/20 0.87
▸ EZH1 Q92800 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15700354 0.93 EZH2 (0.87) EZH2EZH1
SCHEMBL13276887 0.93 EZH2 (1.00) EZH2EZH1
SCHEMBL17136198 0.92 EZH2 (0.92) EZH2EZH1
SCHEMBL15700359 0.91 EZH2 (0.88) EZH2EZH1
SCHEMBL13277938 0.91 EZH2 (0.91) EZH2EZH1
SCHEMBL17136259 0.91 EZH2 (0.85) EZH2
SCHEMBL15700351 0.88 EZH2 (0.94) EZH2EZH1
SCHEMBL13280847 0.88 EZH2 (1.00) EZH2
SCHEMBL15700371 0.88 EZH2 (0.92) EZH2EZH1
SCHEMBL17136159 0.88 EZH2 (0.84) EZH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240165121-A1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2024-05-23 — — US disclosed
US-11642348-B2 Substituted benzene compounds Epizyme, Inc. (US) 2023-05-09 — — US disclosed
US-20210060027-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2021-03-04 — — US disclosed
EP-3725314-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2020-10-21 — — EP disclosed
EP-2906537-B1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2020-03-11 — — EP disclosed
US-10092572-B2 Substituted benzene compounds Epizyme, Inc. (US) 2018-10-09 — — US disclosed
US-20150284370-A1 SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2015-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284370-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL EZH2 2519/4885EZH1 1276/4885
US-10092572-B2 Substituted benzene compounds CYP1B1, TP53, VHL EZH2 2519/4885EZH1 1276/4885
US-20210060027-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL EZH2 2519/4885EZH1 1276/4885
US-20240165121-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL EZH2 2519/4885EZH1 1276/4885
US-11642348-B2 Substituted benzene compounds CYP1B1, TP53, VHL EZH2 2519/4885EZH1 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback